|
|
FDA Approves Kelnor(TM) as New Oral Contraceptive
May 25, 2005, 20:36, Reviewed by: Dr.
|
|
Kelnor 1/35 (28 day regimen) Tablets provide a continuous oral contraceptive regimen containing 21 light yellow tablets of 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and 7 white tablets of inert ingredients.
|
By Barr Pharmaceuticals, Inc.,
Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic
version of Pfizer's Demulen(R) 1/35-28 (Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP, 1mg/35mcg) oral contraceptive.
The Company will launch the product as a branded generic using the Kelnor(TM) trademark. The Company's portfolio of generic oral contraceptives currently totals 22 products.
Kelnor 1/35 (28 day regimen) Tablets provide a continuous oral contraceptive regimen containing 21 light yellow tablets of 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol, and 7 white tablets of inert ingredients.
Kelnor is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Kelnor will compete in a market that had total annual sales of approximately $52 million for the twelve months ending March 2005, based on IMS sales data. 
- U.S. Food and Drug Administration (FDA)
www.barrlabs.com
Barr Pharmaceuticals, Inc., a holding company that operates through its principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals.
Forward-Looking Statements
Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non-infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the
preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability
of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing
activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual
Report on Form 10-K for the fiscal year ended June 30, 2004.
The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
